Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Qu...
April 24 2018 - 7:30AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that it plans to report its financial results for its
fiscal second quarter ended March 31, 2018, after the U.S. markets
close on May 8, 2018. Enanta management will host a conference call
at 4:30 p.m. ET to discuss these results and provide an update on
Enanta’s business, including its research and development
pipeline.
Conference Call and Webcast InformationTo participate in
the live conference call, please dial (855) 840-0595 in the U.S. or
(518) 444-4814 for international callers. A replay of the
conference call will be available starting at approximately 7:30
p.m. ET on May 8, 2018, through 11:59 p.m. ET on May 11, 2018 by
dialing (855) 859-2056 from the U.S. or (404) 537-3406 for
international callers. The passcode for both the live call and the
replay is 3238478. A live audio webcast of the call and replay can
be accessed by visiting the “Events and Presentation” section on
the “Investors” page of Enanta’s website at www.enanta.com.
About Enanta
Enanta Pharmaceuticals has used its robust, chemistry-driven
approach and drug discovery capabilities to become a leader in the
discovery of small molecule drugs for the treatment of viral
infections and liver diseases. Two protease inhibitors, glecaprevir
and paritaprevir, discovered and developed through Enanta’s
collaboration with AbbVie, have now been approved in jurisdictions
around the world as part of AbbVie’s direct-acting antiviral (DAA)
regimens for the treatment of hepatitis C virus (HCV) infection,
including the regimens marketed as MAVYRET™ (U.S.) and MAVIRET™
(ex-U.S.), and (glecaprevir/pibrentasvir) and VIEKIRA PAK®
(paritaprevir/ritonavir/ombitasvir/dasabuvir) (U.S.) and VIEKIRAX®
(paritaprevir/ritonavir/ombitasvir) (ex-U.S.).
Royalties from the AbbVie collaboration are helping to fund
Enanta’s research and development efforts, which are currently
focused on the following disease targets: non-alcoholic
steatohepatitis (NASH), primary biliary cholangitis (PBC),
respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Please visit www.enanta.com for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180424005104/en/
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.comorMedia ContactMacDougall
Biomedical CommunicationsKari Watson,
781-235-3060kwatson@macbiocom.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jul 2023 to Jul 2024